

CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

Date: 02.09.2020

To,
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

(BY BSE LISTING CENTRE)

Sub: Outcome of the Board Meeting held on Wednesday, 02nd September, 2020 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Respected Sir/Ma'am,

The Board of Directors of the Company in their meeting held on Wednesday, the 02nd day of September, 2020, which commenced at 04:00 P.M. and concluded at 05:00 P.M. *inter-alia*, transacted the following business:

1. Approved the Un-audited Financial Results of the company for the quarter ended on 30th June, 2020 and took on record Limited Review Report thereon. (Copy of the same Enclosed herewith).

Further, the extract of the above results would also be published in the newspapers in compliance with Regulation 47 of "Listing Regulations".

2. Recommended to shareholders the appointment of Mr. Mahavir Pratap Sharma as Independent Director of the company for a period of 5 (five) years.

It is also confirmed herewith that Mr. Mahavir Pratap Sharma, being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

3. Approved convening of 29th Annual General Meeting of the Company on Wednesday, September 30, 2020 at 12:30 P.M. through Video Conferencing / Other Audio Visual Means facility and matters connected therewith.
4. Approved the closure of register of members and share transfer books of the Company from Thursday, September 24, 2020 to Wednesday, September 30, 2020 (both days inclusive) for the purpose of 29th Annual General Meeting.
5. Approved the Board's Report for the financial year 2019-20.

For SARDA PROTEINS LTD.


Company Secretary

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)

Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)

Contact No.: +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com

CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.


TRADING WINDOW:

Further in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's code of conduct for Prohibition of Insider Trading the "Trading Window" for trading in the shares of the Company will open from 05th September, 2020 for all Designated Persons, their immediate relatives and other connected person (s).

You are requested to kindly take the same on record.

Thanking you,
Yours faithfully,

FOR SARDA PROTEINS LTD
For SARDA PROTEINS LTD.


Company Secretary

AMIT KUMAR MODI
COMPANY SECRETARY &
COMPLIANCE OFFICER
M.NO.: 29371

Encl: a/a

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)

Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)

Contact No.: +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com



Khetawat Agarwal & Co.
Chartered Accountants

Limited Review Report
Unaudited Standalone Quarterly and Year to Date Results

To
The Board of Directors
Sarda Proteins Ltd

We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter ended 30th June 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khetawat Agarwal & Co.

Chartered Accountants

FRN: 003960C




M.L. Agarwal
Partner

M. No.: 072854

UDIN : 20072854AAAAW9876

Place : Jaipur

Date : 02.09.2020



Office: 103, 1st Floor, City Centre, Ashok Circle, Alwar - 301001 (Rajasthan)

Phone : Office 0144-2340924, 7014347644

Mobile: 9414215353 (ML Agarwal)

E-mail : khetawatagarwal21@gmail.com

SARDA PROTEINS LIMITED

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
Corporate office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)
Phone: +91 7737822222, Email: sardaproteins@yahoo.com, website: www.sardaproteins.com

CIN: L15142RJ1991PLC006353

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30TH JUNE 2020

Rs.in Lakhs

Particulars	Three Months Ended on	Preceding Three Months Ended on	Corresponding Three Month	Year Ended
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
	Un-Audited	Audited	Un-Audited	Audited
I. Revenue from operations	-	188.61	37.75	540.03
II. Other Income	2.01	1.98	0.01	8.02
III. Total Revenue (I+II)	2.01	190.59	37.76	548.05
IV. Expenses:				
Cost of Material Consumed	-	-	-	-
Purchase of Stock -in- Trade	-	174.39	37.25	512.69
Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	-	-	-	-
Employee Benefit Expenses	2.84	0.23	3.37	9.06
Finance Cost	-	0.18	0.01	0.21
Depreciation and Amortisation Expenses	0.08	0.08	0.20	0.33
Other expenses	3.19	2.28	4.22	8.72
Total Expenses (IV)	6.11	177.16	45.05	531.01
V. Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	(4.11)	13.43	(7.29)	17.04
VI. Exceptional Items	-	-	-	-
VII. Profit/(Loss) before Extraordinary Items and Tax (V-VI)	(4.11)	13.43	(7.29)	17.04
VIII. Extraordinary Items	-	-	-	-
IX. Profit/(Loss) before Tax (V-VI)	(4.11)	13.43	(7.29)	17.04
X. Tax Expense:				
(1) Current Tax	-	2.66	-	2.66
(2) Deferred Tax	-	11.09	-	11.09
XI. Profit/(Loss) for the period from Continuing Operations (VII-VIII)	(4.11)	(0.32)	(7.29)	3.29
XII. Profit/(Loss) from Discontinued Operations	-	-	-	-
XIII. Tax Expenses of Discontinued Operations	-	-	-	-
XIV. Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-
XV. Profit/(Loss) for the period (IX+XII)	(4.11)	(0.32)	(7.29)	3.29
XVI. Other Comprehensive Income				
A (i) Items will not be reclassified to Profit or Loss	-	-	-	-
(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-
B (i) Items will be reclassified to Profit or Loss	-	-	-	-
(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-
Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other comprehensive income for the period)	(4.11)	(0.32)	(7.29)	3.29
Paid up Equity Share Capital (Face Value of the Share-Rs. 10 Per Share)	172.59	172.59	172.59	172.59
XVIII Earnings per Equity Share				
(1) Basic	(0.24)	(0.02)	(0.42)	0.19
(2) Diluted	(0.24)	(0.02)	(0.42)	0.19

Notes:

- The above results were approved by Audit Committee and Board of Directors in their meeting held on 02nd September 2020.
- Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
- Segment Results as per AS is not applicable, as company dealing in only one segment i.e. "Agro Products".
- No Investor Complaints were received during the quarter ended 30-Jun-2020 nor any pending as on 01-Jul-2020.
- Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.
- Due to the COVID-19 situation business of the company was been impacted during the quarter, and not achieved any business deal during the quarter.

Place: Jaipur
Date : 02nd September-2020



For and on behalf of the Board
Sarda Proteins Ltd

Deepak Data (DIN: 01672415)
Managing Director



UDIN:-20072854AAAAW9876